The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 7, 2023. Its latest SEC filing is a SC 13D/A from Nov 22, 2023.
10-Q for Q2 FY2023, filed Aug 7, 2023
The sections below describe the company as of the FY2022 annual report.
Developed medicines for rare, severe kidney diseases, including IgA nephropathy and hyperoxaluria, for patients with kidney disorders.
10-K for FY2022, filed Feb 27, 2023
Revenue came mainly from collaboration and licensing agreements: partners paid for licenses, research and development services, and manufacturing supply, while agreements also provided milestone payments and royalties on licensed-product sales.
10-K for FY2022, filed Feb 27, 2023We have not generated any revenue from product sales. Our revenue to date has been primarily derived from our collaboration and license…View ↗
In November 2021, we entered into a License Agreement with SanReno, or the China License Agreement. The China License Agreement includes…View ↗
Prior to the completion of the Merger, Aduro generated revenue from collaboration and license agreements. These collaboration agreements…View ↗
In November 2021, we entered into a License Agreement with SanReno (“China License Agreement”). In addition, we assumed several existing…View ↗
$6.1M
10-K for FY2022, filed Feb 27, 2023
$6.1M ↗
License and collaboration partners, including SanReno, were counterparties to agreements for kidney-drug licenses, research and development services, and manufacturing supply.
10-K for FY2022, filed Feb 27, 2023In November 2021, we entered into a License Agreement with SanReno, or the China License Agreement. The China License Agreement includes…View ↗
Prior to the completion of the Merger, Aduro generated revenue from collaboration and license agreements. These collaboration agreements…View ↗
In November 2021, we entered into a License Agreement with SanReno (“China License Agreement”). In addition, we assumed several existing…View ↗
No. It lost $187.9M in FY2022.
10-K for FY2022, filed Feb 27, 2023
−$185.1MView ↗
10-K for FY2022, filed Feb 27, 2023
−$187.9MView ↗
10-K for FY2022, filed Feb 27, 2023
−$119.1MView ↗
10-Q for Q2 FY2023, filed Aug 7, 2023
−$66.9MView ↗
8-K, filed Aug 11, 2023
At the effective time of the Merger (the “Effective Time”), each issued and outstanding share of Chinook common stock (other than shares…View ↗
Shrank. Revenue fell 59% in 4 years, from $15.1M in FY2018 to $6.1M in FY2022, about 20% a year.
From immunotherapy to kidney medicines
The older report described an immunotherapy pipeline based on STING and APRIL pathways for cancer, autoimmune and inflammatory diseases; the later report centered on precision medicines for rare, severe kidney diseases.
10-K for FY2019, filed Mar 9, 2020 10-K for FY2022, filed Feb 27, 2023We are an immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the…View ↗
Chinook is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for kidney…View ↗
Competes with Calliditas Therapeutics, Travere Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals, F. Hoffman-La Roche, Novartis, Omeros, Vera Therapeutics, RemeGen, Alpine Immune Sciences, and Otsuka Pharmaceutical
10-K for FY2022, filed Feb 27, 2023If our lead product candidate atrasentan is approved for the treatment of IgAN, it may compete with other products used to treat this…View ↗
Loading...
